Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years

NCT04466085 is registered in ClinicalTrials.gov with Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd. as lead sponsor.

NCT NCT04466085
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT04466085 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Randomized, Blinded, Placebo-controlled Trial to Evaluate the Immunogenicity and Safety of a Recombinant New Coronavirus Vaccine (CHO Cell) With Different Doses and Different Immunization Procedures in Healthy People Aged 18 to 59 Years
Lead sponsor
Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.
Phase
Phase 2
Overall status
Unknown status
Start date
July 12, 2020
Completion date
December 15, 2021
Enrollment
900 (actual)
Sites
1

Conditions

As the registry lists them; a condition with its own page is linked.

coronavirus